{"id":2163,"date":"2017-06-08T17:10:14","date_gmt":"2017-06-08T11:40:14","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2163"},"modified":"2021-07-24T12:56:46","modified_gmt":"2021-07-24T07:26:46","slug":"the-business-cocktail-26","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-26","title":{"rendered":"AZ offloads; Pfizer&#8217;s deal; Takeda\u2019s work on plant; Germany&#8217;s doc payment"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f999c5c2cf9\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f999c5c2cf9\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-26\/#AstraZeneca_offloads_headache_drug_Zomig_to_Grunenthal_to_raise_300M_cash\" >AstraZeneca offloads headache drug Zomig to Gr\u00fcnenthal to raise $300M cash<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-26\/#Pfizers_14B_Medivation_deals_now_a_cautionary_M_A_tale_thanks_to_ASCO\" >Pfizer&#8217;s $14B Medivation deal&#8217;s now a cautionary M&amp;A tale, thanks to ASCO<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-26\/#Takeda_starts_work_on_E40M_plant_to_produce_multiple_myeloma_drug_Ninlaro\" >Takeda starts work on \u20ac40M plant to produce multiple myeloma drug Ninlaro<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-26\/#Germanys_doc_payment_transparency_effort_relies_on_honesty\" >Germany&#8217;s doc payment transparency effort relies on honesty<\/a><\/li><\/ul><\/nav><\/div>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"AstraZeneca_offloads_headache_drug_Zomig_to_Grunenthal_to_raise_300M_cash\"><\/span>AstraZeneca offloads headache drug Zomig to Gr\u00fcnenthal to raise $300M cash<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">AstraZeneca had some positive news to announce at ASCO about its PARP Lynparza for treating breast cancer, but all in all, the U.K. company continues to struggle and so will sell yet another asset to raise cash while CEO Pascal Soriot works to right the ship. The U.K drugmaker today said that it has a deal to sell Germany\u2019s Gr\u00fcnenthal rights to its migraine treatment Zomig for all markets outside of Japan. AZ will get $200 million when the deal is done and up to $102 million in additional payments if targets are hit. The arrangement includes rights to the drug in the U.S. where it has been licensed to Impax Pharmaceuticals since 2012. Impax will continue to market Zomig in the U.S. AstraZeneca will continue to manufacture and supply it, during the transition.\u00a0 Gr\u00fcnenthal\u2019s experience with pain drugs puts them in a good position to serve patients that rely on the headache med, Mark Mallon, executive VP of global product &amp; portfolio Strategy at AstraZeneca said in a statement.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Pfizers_14B_Medivation_deals_now_a_cautionary_M_A_tale_thanks_to_ASCO\"><\/span>Pfizer&#8217;s $14B Medivation deal&#8217;s now a cautionary M&amp;A tale, thanks to ASCO<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">The annual ASCO meeting often throws new light on old drugs\u2014and old dealmaking. This year, it\u2019s last summer\u2019s most ballyhooed M&amp;A deal\u2014Pfizer\u2019s $14 billion buyout of Medivation\u2014that doesn\u2019t look so impressive anymore, thanks to data rolled out over the weekend. Big pharma and big biotech bidders swarmed on Medivation back then, partly because of its pipeline med talazoparib, a PARP inhibitor then-Medivation chief David Hung touted as a best-in-class med. The other big draw was Xtandi, the blockbuster-to-be prostate cancer drug, and its present-day cash flow. The two together added up to offers from Pfizer and Sanofi, plus a range of other bidders rumored to include Amgen and Gilead Sciences. Thing is, Xtandi competes head-to-head with Johnson &amp; Johnson\u2019s Zytiga, and while Xtandi put up disappointing data in a study that might have helped grow sales, Zytiga racked up a couple of study wins at ASCO that analysts now say could help the J&amp;J med zoom ahead on the indication front.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Takeda_starts_work_on_E40M_plant_to_produce_multiple_myeloma_drug_Ninlaro\"><\/span>Takeda starts work on \u20ac40M plant to produce multiple myeloma drug Ninlaro<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Japanese drugmaker Takeda has started work on a new plant to produce its oral multiple myeloma drug Ninlaro, a first-to-market active proteasome inhibitor, and expects the facility will be ready to ship the potential blockbuster next year or in early 2019.\u00a0 The company says construction begins this month on the \u20ac40 million ($42.8 million) facility at its Grange Castle site in Dublin to manufacture Ninlaro. The plant is slated to be completed in the second quarter of 2018 and be operational to ship secondary packaged product in the second half of fiscal 2018, which ends on March 31, 2018. Ireland development authorities boasted in December that Takeda was expanding in the country, but the drugmaker is now offering up more details on the project. It said the 5,672-square-meter (61,053-square-foot) production facility will house the API, formulation, primary and secondary packaging and quality-control processes. The company will add 40 jobs at the site as a result of the expansion.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Germanys_doc_payment_transparency_effort_relies_on_honesty\"><\/span>Germany&#8217;s doc payment transparency effort relies on honesty<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">In the U.S., the Open Payments database lays out pharma&#8217;s payments to doctors for all to see. In Germany, where disclosure isn&#8217;t mandated as it is in the U.S., a nonprofit is trying transparency based on the honor system. German doctors will be able to voluntarily disclose contributions from pharma in a database compiled by the nonprofit journalism organization Correctiv, according to Germany\u2019s DW. About 71,000 doctors in the country received \u20ac575 million in cash or in-kind contributions from the drug industry last year, a Correctiv investigation found in December. That&#8217;s far less than the $7.52 billion that drug and device makers funneled to doctors and healthcare providers in the U.S. in 2015, the most recent data available, but slightly more than the \u00a3345 million that changed hands in the U.K. Making those payments public at the doctor-by-doctor level is important, advocates say, because studies show financial relationships between drug makers and doctors can affect physicians&#8217; prescribing habits.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca offloads headache drug Zomig to Gr\u00fcnenthal to raise $300M cash AstraZeneca had some positive news to announce at ASCO about its PARP Lynparza for treating breast cancer, but all in all, the U.K. company continues to struggle and so will sell yet another asset to raise cash while CEO Pascal Soriot works to right [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1981,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17537,96,924,410,17412,460,712,843,554,17536],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-2163","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-asco","tag-astrazeneca","tag-germany","tag-multiple-myeloma","tag-ninlaro","tag-pfizer","tag-pharma-industry","tag-sale","tag-takeda","tag-talazoparib","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AZ offloads; Pfizer&#039;s deal; Takeda\u2019s work on plant; Germany&#039;s doc payment<\/title>\n<meta name=\"description\" content=\"AstraZeneca had some positive news to announce at ASCO about its PARP Lynparza for treating breast cancer, but all in all, the U.K. company...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-26\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AZ offloads; Pfizer&#039;s deal; Takeda\u2019s work on plant; Germany&#039;s doc payment\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca had some positive news to announce at ASCO about its PARP Lynparza for treating breast cancer, but all in all, the U.K. company...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-26\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-06-08T11:40:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/06175059\/mergers_and_acquisitions-post16.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"720\" \/>\n\t<meta property=\"og:image:height\" content=\"370\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AZ offloads; Pfizer's deal; Takeda\u2019s work on plant; Germany's doc payment","description":"AstraZeneca had some positive news to announce at ASCO about its PARP Lynparza for treating breast cancer, but all in all, the U.K. company...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-26","og_locale":"en_US","og_type":"article","og_title":"AZ offloads; Pfizer's deal; Takeda\u2019s work on plant; Germany's doc payment","og_description":"AstraZeneca had some positive news to announce at ASCO about its PARP Lynparza for treating breast cancer, but all in all, the U.K. company...","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-26","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-06-08T11:40:14+00:00","article_modified_time":"2021-07-24T07:26:46+00:00","og_image":[{"width":720,"height":370,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/06175059\/mergers_and_acquisitions-post16.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-26","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-26","name":"AZ offloads; Pfizer's deal; Takeda\u2019s work on plant; Germany's doc payment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-26#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-26#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/06175059\/mergers_and_acquisitions-post16.jpg","datePublished":"2017-06-08T11:40:14+00:00","dateModified":"2021-07-24T07:26:46+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"AstraZeneca had some positive news to announce at ASCO about its PARP Lynparza for treating breast cancer, but all in all, the U.K. company...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-26"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-26#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/06175059\/mergers_and_acquisitions-post16.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/06175059\/mergers_and_acquisitions-post16.jpg","width":720,"height":370},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/06175059\/mergers_and_acquisitions-post16-300x154.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ASCO<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Germany<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Multiple Myeloma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ninlaro<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharma Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">sale<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Takeda<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Talazoparib<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">ASCO<\/span>","<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Germany<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma<\/span>","<span class=\"advgb-post-tax-term\">Ninlaro<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Pharma Industry<\/span>","<span class=\"advgb-post-tax-term\">sale<\/span>","<span class=\"advgb-post-tax-term\">Takeda<\/span>","<span class=\"advgb-post-tax-term\">Talazoparib<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jun 8, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jun 8, 2017 5:10 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2163"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2163\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1981"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2163"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2163"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}